Securities and Exchange Board of India (SEBI) has barred Transgene Biotek and its directors from securities market in a case related to fund diversion through global depository receipts by the firm. Besides, Transgene will continue the measures to recall outstanding amount of $38.5 million and bring the money back into its bank account in India within a period of one year from the date of this order.

The regulator further directed the firm to continue to be restrained from the markets till the compliance of the direction and thereafter for an additional period of two years from the date of bringing back the money.

Transgene Biotek (TBL) is engaged in manufacturing drugs.

Related Transgene Biotek Ltd. Links:

Transgene Biotek Share Price

3.57 -0.12 (-3.25%) Mar 08, 18:37
1 Year Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 2866.70
Aster DM Healthcare 141.15
Narayana Hrudayalay 414.40
Dr Lal Pathlabs 2315.25
Metropolis Health. 1911.25
View more..
Sensex vs Transgene Biotek
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback